Scientists from the Helmholtz Institute for RNA-based Infection Research (HIRI) and the Julius Maximilian University (JMU) in Würzburg have paved the way for a new diagnostic platform that enables the detection of multiple markers in one single test.
Join Europe's Knowledge Transfer community at the sector's premier annual event uniting experts, professionals, and industry from around the world. The new office ticket allows you to participate with the whole team for just 1,500 EUR.
Heidelberg Pharma AG is allowed to initiate a Phase I/IIa clinical study in the US to evaluate the dosing, safety and anti-tumour efficacy of its lead candidate HDP-101 in multiple myeloma.
16 partners from academia and industry will closely collaborate to prepare a future generation of scientists with outstanding skills in both machine learning and chemistry, to create new AI methods for drug research.
Ascenion, technology transfer partner of Hannover Medical School (MHH), has supported the conclusion of a collaboration and licence agreement between MHH and Novo Nordisk.
As part of its ‘GO-Bio initial’ programme, the BMBF has awarded Ascenion funding for its 'Life Science Digital Hub' concept to improve support for GO-Bio initial applicants.
Ascenion’s portfolio company HepaRegeniX achieves an important preclinical milestone indicating beneficial therapeutic effects of its lead candidate in certain liver carcinomas.
An innovative approach to combat infections caused by Staphylococcus aureus will receive funding of initially 1.33 million USD plus an additional 7.44 million USD, depending on project progress. It is jointly developed by the HZI and the LDC.
Ascenion will support eight members and four partners of the Innovative Training Network (ITN) ‘SMABEYOND’ in all aspects relating to the intellectual property and potential commercialization of their work.